water, and body fat are increased, resulting in a hi gher vo lu me of distribution and a lower serum concentration for any given dose of dru g. T h is increases th e volume of fluid which the kidney must in some cases clear o f drug (8) . This may or may not be counterbalanced by the steady increase in renal bl ood flow and glomerular filtration rate which tend to speed th e clearan ce of free drug. Although albumin production is normal or increased, pla sm a albu m in concentration falls and total plasma drug concentration is d ecreased. If t he total circulating albumin is reduced, as by pre-eclampsia or th e neph rotic syn drome , binding sites can become saturated and free drug fracti o n r ises (9) . The hormonal milieu of pregnancy is thought to increase metab ol ic ac tivity in th e liver (8) and may tend to speed breakdown of some drugs.
Fetal physiology and risk. Further complicating the use of d rugs in p regna ncy is the presence of an additional but equall y complex patient, t he fetus. All psychotropic drug classes cross the placenta. Transfer occurs primari ly by simple diffusion , dependent upon the che m ica l properties o f th e drug (including molecular size, protein-binding affinity, polarity , and lipid so lub ility), drug concentration, and duration of exposure (10) . Non-ionized, low mol ecu lar weight, lipid-soluble drugs are well absorbed. Placental metaboli sm of d rugs is probably less active than metabolism within the fetal liver. Inte nd ed or unintended drug e ffects may act to reduce placental blood flow o r interfere with active transport and other nutritive functions of the placenta.
Compared to the adult, fetal cardiac output is greater a nd a hi gher proportion of blood flow is distributed to the brain. Combined with greater blood-brain permeability this leads to more rapid and more co mp lete drug exposure of the fetal brain (11) . Total concentration of plasma p r ote in and protein-binding affinity are less in the fetus than in th e mother , lea vin g more free drug available for tissue penetration and competition with o t her d rugs and endogenous compounds for protein binding (10) . Drugs are metaboli zed chiefl y in the fetal liver, where the activity and concentration of ce r tain microso ma l enzymes is less than in the adult, prolonging and exagge ra ting drug effects. Excretion of most drugs, via the placenta and fetal urine, is delayed.
Like the fetus, the neonate has proportionally less total ser um p ro tei n for binding, less active hepatic degradative enzymes, and lower glomerular filtration rate than the adult (9) . The blood-brain barrier is still incomplete and t he immature central nervous system (CNS) appears generally more se nsi tive to drug effects (10) . Furthermore, the neonate no longer ex ists in equilib rium with its mother via the placenta, and a drug concentrated in th e fe tus shor tly befo re birth may have significantly prolonged postnatal effects.
The risks to the fetus include teratogenic effects, long-term neurobehavioral effects, and direct toxic effects. A teratogenic e ffect may be immedi ate or delayed ; it ma y consist of abortion , malformation, altered fetal growt h, functional deficit, carcinogenesis, or mutagenesis. Psychotropic dru gs ca n also produce long-term functional effects which are not ac compan ied by gross st r uctu ral malformations and which may not be measureable or mani fest for yea rs after bi r th. Since the pioneering studies of Werboff and co lleag ues estab lished th e field of behavioral teratology ( 12, 13) , numerous subsequent an ima l stu d ies have sho wn th at p re natal ex posure to a variety of ps ychoactive drugs can d istu rb nerve ce ll proli fer ation a nd d iffere n tiat io n (14 ), neurot ra nsmitter concentrations (15) , and behavio ral development and performance ( 16, 17) . Such psyc hoteratogenicity ma y be expressed as disturbed psychomotor activity, fau lty adaptation to the extra-uterine environment, abnormal learnin g or p roble m-sol vin g ca pacity, or o ther mo re sub tle cognitive deficits a nd mood di sturban ces.
In hum an s, alcohol, o piates, and d ip henyl hydantoin are already welles tab lished psych o terato ge ns, ca pa b le of p roducing disturbances of arousal a nd motor coord ination as well as specific learn in g disabilities and mental reta rdat ion (18) (19) (20) .
Fu ncti o nal behavioral o r psych o lo g ical effects may occur at drug do ses lower than t hose required to p roduce struct ural d e fect s (2 1), or they ma y ari se wh en expos u re occu rs afte r th e period of o rga nogenesis b u t during the latter hal f of p regnancy o r early postn at al life when CNS d e vel opme n t and maturation is st ill ongoi ng . Effec ts may even be so su b t le as to be manifest only if th e po st-natal environ men t is enriched or impoverished (22) making routine detection di fficul t. Eve n drugs whi ch induce only transient early behavioral cha nges may lead to permanent beha vioral conseq uences through disturbance of earl y e nv iro n men ta l, includi ng m other-infant, in teractio ns. Neonatal depression (2 3), h yperacti vit y, and irritability, as we ll as mood or be havior disturbances may all interfe re with the ea rly mo th er-infa n t relationshi p .
Rel ativel y little atten tio n has been given to studying the long-term neurobehavioral an d psych olog ical effects in humans of pre-natal exposure to t he antipsyc hotics, antidepressants, and lithium. T he few follow-up stu d ies a vaila ble will be d iscu ssed unde r the d rug classes to whic h t hey apply, but th e clinician should be awa re that o u r kn o wledge in this area is inadequate and the im p lica tio ns for ex posed o ffsp ri ng are po tentiall y grave. Not only is ca u tion in prescribing adv ised, but long-term , syste matic fo llow-up of the ch ild ren is cruc ia l.
Direct tox ic effects on the fetus an d neonate include the potentiall y reversib le, dose-re lated effects which m ay be exaggerated by the immature fetal and neo natal metabolism . Drugs ad m inistered at or near term may concentrate in th e fetus, and afte r d eli very, when clearance d epe nd s upon immatu re neonatal mech a nism s, dru g effects may be prolonged . Chronic prenatal admi nist ra tion ma y lead to feta l d e pe nd e nce and ultimately neonatal withdrawal symptoms when drug ex posure ceases at b irth .
Methodological difficulties. The ca lculation of a specific ri sk and su m ma tion of a to ta l r isk to th e pat ien t and her fetus is a difficult, if not impossible , ta sk. For ethical reaso ns, randomized p ro spect ive clinical trials of ps ychotropic drug effects o n pregnant wome n have not and should not be performed . Animal studies can be carefully controlled and may suggest a potential r isk, bu t species differences can be profound and extrapolation from animal stud ies is always tentative.
To date, all human studies on the effects of psychotropic drugs in pregnancy suffer from poor control of potentially confounding var ia bles suc h as maternal age, gravidity, and parity, as well as history of miscarriages, still births, and prior malformed infants. Maternal nutrition , alcohol use , cigarette use , an d over-the-counter and prescription drug use all need to be carefully contr oll ed or at least matched. The dose of drug, duration of exposure , and timing of exposure are critical variables, exemplified by thalidomide's ab ility to produce limb defects only between the 42nd and 48th days of gestation (24) . Thus a study which combines all first trimester drug exposures ma y miss a sub tle effect produced only during a brief gestational " wind o w." The mother's illn ess and the indication for drug use is another often neglected variabl e. Many of the studies on phenothiazine effects were carried out on patients with nausea and vomiting rather than a mental disorder. These doses were lower, and duratio n of treatment shorter, than those relevant to treatment at mental illness. Fina lly, the length and thoroughness of follow-up is generally inadequate . As Ed lund and Craig (25) have shown, the cumulative incidence of congenital anomalies increases with increasing length of follow-up. Therefore, if we hope to detect subtle or delayed neurobehavioral effects in children exposed p renatall y to psychotropic drugs, our observations must be both ext ensive , in te rms of neurobehavioral assessment techniques, and extended, ideall y into ad u lt hood .
ANTIPSYCHOTIC DRUGS
Indications. The antipsychotic drugs have repeatedly been shown e ffec tive in the treatment of acute psychotic episodes occurring in schizo p h ren ic, affective, and a variety of other mental disorders (26) . They have been used effectively to treat psychotic symptoms in pregnant women as well.
Adverse Effects on Mother. Sedation, postural h ypotension , antich ol inergic and extrapyramidal symptoms may occur. Anticholinergic e ffec ts on th e bowel ma y worsen the constipation which is common in pregnancy. Lik ewise the sedative effect ma y compound the pregnant woman 's fatigue . Most impo r ta n t, however, is the potential effect on maternal blood pressure , and th e pote nt ial compromise of placental blood flow should always be kept in mind. The ri sk of tardive dyskinesia of course always pertains.
Teratogenic Effects. Phenothiazines and thioxanthenes have been shown to pass the placental barrier (27, 28) and phenothiazines have been measu red in va r io us concentrations in fetal brain and liver.
Most reviews of the use of chlorpromazine, haloperidol , o r perphenazine in human pregnancy find no statistically significant increase in th e inc iden ce of major congenital structural malformations in exposed offspring (29 -36) . In a prospective survey of 12 ,764 pregnant women , Rumeau-R ouque tte and associates (37) found a statistically significant increase in the numbe r of infants born with m aj o r malformations when exposed prenatally to phenothia zin e s with a three-carbon a lip hatic side chain (chlorpromazine, methotrimepra zin e , tr irneprazine, and oxomemazine). Compared to non-exposed co n trols, a similar increase was not observed with promethazine or the pipe razine and p ip e r id ine antipsychotics . Of the implicated drugs, on ly chlorproma zin e is used as an a ntipsychotic in the United States, and a lt hough this study might provid e reason for avoiding ch lorpromazine, many confounding factors a mong those women were not considered. Probably the best controlled stu dy to d ate is t he one by Milkovich and van den Berg (38) . Among 20 ,504 pregnant women fo llowed p rosp ect ivel y, 19 ,9 5 2 were t reated for nausea a nd vomiting durin g th eir first trimester, mostly with phenothiazines and especiall y prochlorpe r a zine. Maternal age, type of drug, and gestational age at e x posu r e were co ntrolle d . They found no increase in the rates of severe congenital anomal y and p erin atal d eat h fo r th e exposed group co m pared to controls. However, no doses were re corded and co mpliance was not assessed. When use d as antiemetics, the pheno th ia zines are likel y to be used intermittently and in lower doses than those n eeded for the treatment of psychosis.
Long-Term Neuro behavioral Effects. Animal studies h a ve found that prenatal exposure to antipsychot ic d rugs can affect vascu logenesis (39), neuro genesis (4 0 , 41), central catechola mine le vel s ( 15) , and dopamine r e ceptor fu nction (42) . Some ani mal studies report persistent abnorma lities of learning behavior ( 16 , 43,44) 
wh ile others d o not (45).
Data on long-te rm behaviora l consequences in humans is scarce. After se ve r a l case reports of persistent neurobehavioral abnormali ti es in infants of mothers treated with p h e n o th ia zines (46), Desmond and as sociate s (4 7) r epo rted o n 19 in fan ts born to m o th ers o n p henothiazines. Agitation and h ype rtoni cit y persisted for severa l months after birth. Many of these infants were a lso ex posed to alcohol and ba r b it u r a te s in utero, however, and the e ffe ct co u ld not be attributed to a single drug . Stone (36) found no difference in lQ sco res at fo ur years of age b e twe en 151 chi ld ren exposed to phenothiazines in utero a nd con trols who were not exposed. Kr is (48) followed 52 children e xpo sed to low doses (50-150 mg/ day) of ch lorpromazine prenatally, and found no beha vio r al or intellectua l abnormalities. H o we ve r , these represent small samples of chi ld r en, generally exposed to lo w d oses of a ntipsychotic medication at variable ti mes in gestation ; be tte r co ntrolled, more rigorous follow-up studies are needed .
Direct toxic effects on thefe tus and neonate. Direct toxic e ffec ts o f a n tipsychotic d rugs wh ich h a ve been o bserved in n e wb o rns incl ude motor r estle ssn e ss, abnorma l m o veme nts, h ype r to n ia , and tremor (46, (49) (50) (51) . Functi onal bowel obstruction and ne o natal jaundice have also been described (52) . In vitro studies h a ve r a ise d the possibil ity of tox ic effects on ch romosomes (5 3), lymphocyt es (54), an d the feta l r e tin a (55).
R ecommendations. For t he woman with a chronic ps ychotic di sorder or at ri sk for an ac u te psychotic e pisode during pregnancy, early comprehensive obs tetrica l a nd psychi at ri c management and social support should be instituted. Crisis intervention techn iqu es a re use ful at the first sign of deterioration. If th e patie nt is un stabl e , hospi tali zati on a nd use of a th er ape u t ic m ilie u should be tried first.
If psych otic sym p to ms severe enough to th reat e n the life or health of th e woma n or her fetus persist in spi te of aggressive non biologic treatment, t he use
T he treatment goa l is sufficient control of symptoms to e ns u re th e safety of the woman an d her fetus to te rm; it is not necessary or ad visab le to str ive for complete eradicatio n of sym p toms. Anticholinergic medications ma y be used if necessary for treatment of extrapyramidal symptoms, but these medications a lso have potential for toxic effects on t he fetus . Avoid the use o f other medications.
T here is co nsiderab le ev idence that maintenance use of antipsych o t ic medicat ions after rem ission of the ac u te p hase he lps prevent relapse , bu t mainten an ce drug treatment should be based o n the severity of symptoms, the chronicity of th e illness, and th e availability of soc ial support systems. Consid er th e natural h istory of the individual patient's illness, and reduce or di scontin ue th e medication if at a ll poss ib le .
ANT IDE P RESSANTS
In dications. H etero cyclic antidepressants are generall y the treatment of first choice for maj o r depression and the depressed p hase of bipolar disorder. T hey have also fo u nd th e rapeutic usefuln ess in d ysth ym ic d isorders, atypical d epressions, perso nality di so rder s with dep ressed mood , panic and phobic disorde rs, obsessive-co m p u lsive di so rders, chron ic pa in syndromes, and depression in schizophrenia an d sch izo-affective di sorders (26, 56) . They ma y be indicat ed in pregnancy when th e mother's depression is severe enough to threaten the life and hea lth of hersel f and her fe tus . This includes suicidal intent, vegetative and nutri tional d istu rbance , o r severely im pai red functioning and judgemen t not responsive to no nbi ol ogica l interventions including hospitalization .
Adverse effects on the mother. These include anticholinergic effects (dr y mou th , d ecr eased G I motility, mydriasis, cycloplegia, urinary hesitancy or retention, tachycardia, and delirium), orthostatic hypotension and sedation . Imipramine and other tertiary amines more co m mo n ly ca use hypotension and should generall y be avoided in favor of less h ypotensive drugs.
Teratogenic effects. Imipramine and desipramine ha ve been shown to cross the placenta in animals and humans (57, 58) . In at lea st o ne animal study imipramine and desipramine were found to cross the pla centa and to potentiate the pressor response to norepinephrine, whil e amitriptyline and protriptylin e did not. Van Petten (58) noted that even closely related co m po u nds can show differences in penetration of the placenta and subsequent pharmacologi c effects on the fetus. Demonstration of such differences in hum an p regnancies in the future could facilitate th e choice of the antidepressant safes t for the fetus.
Sporadic case reports suggesting a possibl e associati on betwee n ma ternal imipramine or amitriptyline use and fetal limb reducti on de form ities have appeared in th e literature (59, 60) . One retrospective case co ntrol study of 2,784 cases of birth defects was inconclusive (61) , while other sma ll co hort studies (62) (63) (64) (65) found no causal relationship between maternal imipramine or am itriptyline intake and congenital anomalies in th e offspring.
Long-term neurobehavioral effects. Animal st ud ies have clearly demo nst rated that prenatal exposure to tricyclic antidepressants, in th erapeutic doses, can produce behavioral and neurochemical disturbances lasting well past termination of drug exposure and into adulthood. Rats exposed prenatally to im ipramine show decreased h ypothalamic dopamine levels and decrea sed cortical beta adrenergic receptors (66) , delayed reflex development and decr eased exploratory responses (67) , and reduced physiological and behavioral respo nsive ness as adults (68) . Similar results have been obtained after prenatal clomipr am in e exposure (69) . Early neonatal treatment of rats with a monoami ne ox idase inhibitor has resulted in nerve cell changes and decreased co ncentrations of norepinephrine and dopamine in the h ypothalamus, reduced learning ca pa cit y, and diminished emotional reactivity in later life (70) (71) (72) . Neurobeh avio ral follow-up studies in humans have not been done .
Recommendations. Antidepressants should be rese rved fo r th e preg nant woman whose depression is severe eno ugh to threaten th e life and heal t h of herself and her fetus, and which is unresponsive to non biolo gic interventions. Reactive depressions or biological depressions th at are less severe should be treated with psychotherapy alone or in a th erapeutic mili eu. A ca reful his tory, especially of cardiac diseases, review of syste ms, ph ysical exam ination and EKG should precede the initiation of treatment. Inquire about a prior respo nse to a spe cific antidepressant or to ECT.
In general , avoid the tertiary amines (im ipr am ine, amitrip tyline) because of their increased h ypotensive effects. A reasonable choice for card iac safety is trazodone if sedation is desired, desipramine if it is not. These drugs have relatively low anti-cholinergic effects as well. Begin with a low dose and increase slowl y, using plasma drug levels and clinical response to ach ieve the min imal dose effective in relieving the maj or depressive sym ptoms . Monitor pulse, orthostatic blood pressure changes, and EKG if an y abno r ma lity is found on th e baseline EKG. Give the entire daily dose at bedtime if dayt ime sedation is to be avoided or nighttime sedation desired. Divide or reduce th e dose if the patient develops hypotension , h ypertension , arrh ythmias, fainting, or hea r t failure. Persistent adverse cardiovascular effects ma y nece ssitate sto pping th e drug.
Avoid co-administration of other drugs, over-the-counte r o r prescr iptio n , especially those that affect the cardiovascular system. If at all possib le , avoi d the use of antidepressants during the first trimester, and attempt to reduce or discontinue the medication before term. There is a particul arly hi gh ris k of depression in the post-partum period, when resumption of medication and avoidance of breastfeeding may be indicated.
LITHIUM
Indications. Lithium is the drug of choice for prophylaxis against bipol ar affective episodes of the manic type. It also carries FDA approval for use in acute manic episodes and in prophylaxis against the depressive phase of bipol ar disorder (73) . It may also be useful in acute depression for pa tients wh o are unresponsive to other somatic treatments, as proph ylaxis aga in st recurrence of schizoaffective illness, in disorders of impulse control and episod ic violence , and possibly in some a lcoholics.
Approximately one-half of patients with bipolar di sorder are women , and the first manic episode typically occurs before age 30, well with in th e lim its of a woman's reproductive life . Women may first manifest th e di sorder d uring a pregnancy, and may have up to 50 percent risk of developing a post-p artum psychosis which can appear from da ys to weeks follo wing th e birth (2). Practitioners in both obstetrics and in general psychiatry will undoubtedly e ncounter pregnant patients with bipolar disorder.
Adverse effects on mother. Lithium presents the sam e spectr um of side effects and adverse reactions for pregnant women as for others (endoc r ine, rena l, gastro-intestinal, neurologic), but ph ysiological changes in pregnancy may increase the relative risk. Progressively increasing lithium clearance by the kidney may require increasing lithium dose to maintain a th erapeutic ser um concentration. The precipitous fall in glomerular filtration rate and lithiu m clearance after delivery may leave the patient toxic (74) . The use of thiazide diuretics or sodium restriction to treat hypertension or edema of pregnancy may change the fluid and electrolyte balance and quickly lead to maternal and fe tal lithium toxicity (75) .
Teratogenic effects. Lithium freely crosses the placenta, and th e concentrati o n in cord blood equals that of maternal serum (76) .
Lithium has repeatedly been shown to be teratogenic in premammal ia n species, causing abnormal tissue differentiation, di sorganized eNS develo pment, and head and neck anomalies (77 ) . Studies in non-human mammals are contradictory; one showing lithium to be teratogenic (78) , while othe rs do no t (77) . One study showed an adverse effect on human chromosomes in vitro but lithium levels used were in the toxic range.
In order to assess the possible teratogenic e ffect of lithium in h umans, the International Register of Lithium Babies was begun in 1968. Alt hough t he incidence of malformations in babies of untreated mothers with affective disorders is unknown, and although a study of this design cannot produce a true incidence of malformations, pathologic trends ma y be reveal ed (79) . Consecutive reports from 1971 to 1975 revealed increasing likel ih ood th at lithi um exerts a teratogenic effect in humans, especially on the d eveloping ca rdiovascular system (80) (81) (82) . As of 1980, 225 babies exposed to lithium in th e first trimester of pregnancy had been reported to the register, 25 of whom were bo rn with congenital malformations. Besides one baby with intracerebral to xo plasmosis, two with Down's syndrome, and seven stillborn ; 18 of th e 25 ba bies with congenital malformations had involvement of the heart and great vessels, six of them the exceedingly rare Ebstein's anomaly (comprising defect s of th e tr icu spid valve, atrial septum, and right ventricle). Lithium is therefore gen erall y felt likely to be teratogenic with respect to the cardiovascular system wh en admin istered in the first trimester (83 ,84) .
Long-term neurobehavioral effects. A stu dy o f behavioral effects on rats exposed to lithium in utero showed a significant decrease in performan ce o n a T-maze and changes in avoidance behavior (85) , but animal stud ies may not reflect the effects on humans. A case report exists of developmental mo to r d e lay persisting at one year of age in a human infant found to be lith ium to xic at birth, but it is not clear whether the motor delay was due to high lithium levels at b irth or due to cerebral hypoxia associated with lithium-induced cardiac h ypo fun ctio n (86) . A follow-up study of 60 lithium children not malformed at birth did not reveal any significantly increased frequency of ph ysical or mental a no ma lies in the lithium children as compared to sibling controls (87 ) , but co nclusions were based only on mothers' subjective assessments, not ac tua l e xa mi nation or neurobehavioral testing.
Direct toxic effects on the fetus and neonate. Several authors have repo rted neonatal toxicity in the offspring of mothers on toxic or even th erapeutic d oses of lithium at the time of delivery (75, 88, 89) . Findings in th e neonat e incl ude: cyanosis, muscle flaccidity and h ypotonia, poor suck and grasp refl exes, a bsent Moro reflex, and lethargy which may take up to 10 days to r esol ve. Other adverse effects reported in the neonate include atrial flutter (90) , fu nc tio na l tricuspid regurgitation and congestive heart failure (91) , reversibl e in hibitio n of fetal th yroid (92) , and nephrogenic diabetes insipidus whi ch persist ed for two months after birth (93) .
Recommendations. Lithium should be used in pregnant wom en on ly for unequivocal indications, and on ly after careful consideration of all pote nt ial risks and benefits. Women with a history of bipolar disorder have a hi gh ri sk of developing a manic episode off lithium, as studies have sho wn th at 70 percent of patients will have at least one relapse within a year o f dis continuing lit hium ve rs us 20 percent o f th ose who are ma inta in ed o n lithium . A pregnant woma n in a n ac u te manic phase ca n do se r io us harm to h e rsel f and h e r fetus. On the o ther hand , use o f lithium carries multiple poten tial se r io us ris ks to both mother a nd ch ild as o u tlined abov e.
W omen on lithium shou ld be urged to avoid p regnancy and to ma inta in effect ive co ntracep tio n . One wh o pl an s to beco m e pregnant or wh o in ad ve rtentl y becomes pregnant shou ld be with d raw n fro m lithi u m prophylaxis durin g the fir st trim est er unless there is convi nc ing evi dence that doing so wou ld e nda nger the woma n or he r fetus. T he decision to institute , continue , or discontinue lithium ad m inis trat io n in a wo ma n fo r whom p reg na ncy is a fact o r a possibility sho u ld b e made with th e co llaboratio n a nd informed participati on of both t he pati ent a nd h er mate .
If a pregnant wom an d e vel ops a n ac u te manic e pisode , hospitalization wit h a st r uc t u red, sup po rtive mili eu a nd regular indi vidual psyc hotherapy would be ind ica te d first. Judging by cu r ren t ly available e vidence, antipsyc hotic drugs a re probabl y safer th an lithium in the fir st trim est er, a n d mo re rapid ly effecti ve for ac u te mani c symptoms. Choose a lo w-dose, hi gh -p o tency agent at th e low est dose e ffec tive in all eviating dangerous symptoms.
If it is believed safest fo r th e woman a nd h e r fetus to institute lithium treatm ent aft e r th e first third o r h alf of pregna n cy, use the minimum d ose necessa ry to ach ie ve t he d esired th e rapeutic or p r oph ylact ic e ffec t , achie vin g a se ru m le vel o f 0 .7 to 1.2 m Eq/L in mo st cases. A single lit h ium dose sho u ld no t exceed 30 0 mg, g ive n as o fte n as n ecessary to ac hieve the target se ru m concen tration . T his avoids " p u lses" of lith iu m wh ich may be more harm ful to the fe tus th an a steady se rum co ncentra tion . Se ru m lit h iu m le vel s sho u ld be closely m onitored, as ofte n as weekly to ward s th e end of pregnancy a nd even mo re freq uen tl y in th e d a ys befo re te rm . Mo n ito r th yroi d sta tus duri ng pregna ncy an d use th yr oid supp le men t as needed to protect moth er a n d fe tus agains t goite r fo r ma t io n . So di u m-dep let ing diure tics should not be used : sod iu m-rest r icte d d iets shou ld be used o n ly with great ca ution . Red uce th e da ily lithium d ose b y 5 0 percent in the last week of gesta t io n a nd stop complete ly at th e o nse t o fl abor. Reinstitute lithium at pre-pregn an cy d osage (or 50 percent of the te rm dosage if no pre-pregn ancy dose was es ta b lished) as soon after delivery as fluid homeostasis is re-establish ed, usuall y three d a ys.
In co nclusio n , it is not infrequent that a pregnant wo man will develop psychotic or affective sym p toms sev ere e no ugh to threaten th e life or health of h e rself a nd her fe tus. Earl y a nd ag gressive non bi ol ogi c t herap ies, includi ng hospitaliz ation and su pp o r tive mili eu treatm ent, shou ld b e ins titu ted firs t. If th e patient's symptoms persist, the use o f a n a n t ipsychotic, a n tidepressant, or a ntimanic medication shou ld be co ns idered . The d ecision rests upo n a calculation and balanc ing of the ri sks associa te d wit h the untrea ted illness, and th e ri sks ass oc iate d with the drug. T h is paper has a ttem p ted to review th e dat a ava ila b le on the risks o f th ese drugs to th e preg nant woman and he r fetu s, for it is this data upon whi ch cu r rent clinical d ecisions must be made. I have also attempted to stress the limitations involved in most of th e stu d ies to d at e , a nd to suggest the development of more carefull y controlled, more extensively followed-up studies in the future .
